$-0.61
(Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-5 Mln
ROE
-1.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.5
Debt to Equity
0.1
Book Value
$4
EPS
$-10.4
Face value
--
Shares outstanding
1,135,358
CFO
$-169.25 Mln
EBITDA
$-211.33 Mln
Net Profit
$-161.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ampio Pharm (AMPE)
| -- | -- | -- | -- | -89.4 | -90.1 | -71.0 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Ampio Pharm (AMPE)
| -54.5 | -97.3 | -64.2 | 172.7 | 47.7 | -90.2 | 352.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ampio Pharm (AMPE)
|
0.0 | 0.3 | 0.0 | -8.6 | -3,784.9 | -114 | -- | 0.1 |
| 73.9 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 65.3 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 88.9 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,743.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26 | 161.6 | |
| 512.4 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 410.5 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 104.5 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 344.8 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment... of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado. Read more
CEO & Director
Mr. Michael A. Martino
CEO, CFO, General Secretary & Director
Mr. Michael A. Martino
Headquarters
Englewood, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ampio Pharm (AMPE) is $0.01 (NYSE) as of 24-Apr-2026 09:30 EDT. Ampio Pharm (AMPE) has given a return of -89.38% in the last 3 years.
Since, TTM earnings of Ampio Pharm (AMPE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.20
|
0.51
|
|
2022
|
-0.01
|
0.01
|
|
2021
|
-0.02
|
0.01
|
|
2020
|
-0.06
|
0.06
|
|
2019
|
-0.02
|
0.05
|
The 52-week high and low of Ampio Pharm (AMPE) are Rs 0.01 and Rs 0.01 as of 26-Apr-2026.
Ampio Pharm (AMPE) has a market capitalisation of $ 0 Mln as on 23-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ampio Pharm (AMPE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.